Taking stock of the drug industry, from the lab to the medicine chestApril 3, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | FTC tells Illumina to divest Grail, boosting Icahn's case The agency said the $7.1 billion acquisition "would stifle competition and innovation in the U.S. market for life-saving cancer tests." By Matthew Herper STAT+ | A young boy's nightmare diagnosis, and the $3 million one-time treatment that will likely save his life A six-year-old boy was the first to receive a $3 million gene therapy that doctors expect will stave off an otherwise fatal brain disease. By Jonathan Saltzman — Boston Globe STAT+ | Vertex, CRISPR Therapeutics inch ahead of rival for genetic fix to sickle cell disease The first CRISPR treatment for sickle cell disease has been submitted to the FDA, beating a rival gene therapy. By Adam Feuerstein Ryan Pierse/Getty Images STAT+ | The biotech scorecard for the second quarter: 24 stock-moving events to watch What to watch in Q2, including an advisory committee for Sarepta Therapeutics, results from Immunogen, and readouts from Fibrogen. By Adam Feuerstein STAT+ | A devastating skin condition could soon get its first medication, as the frontiers of gene therapy expand Approval is expected for a novel treatment for epidermolysis bullosa, or EB, a genetic condition that causes dangerously fragile skin. By Andrew Joseph More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments